Results 131 to 140 of about 1,228 (155)

Computational Studies on Recent Congeners of Fluoroquinolones and Nitroimidazoles for Their Use in Periodontal Therapy.

J Pharm Bioallied Sci
Natarajan PM.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Early Clinical Experience with Delafloxacin: A Case Series

The American Journal of the Medical Sciences, 2022
The most recently approved fluoroquinolone for use in the US and Europe, delafloxacin (DLX) provides broad-spectrum coverage, improved side effect profile, and excellent potency. Currently approved for the treatment of acute bacterial skin infections and community-acquired pneumonia, DLX may be useful in the treatment of other infections given the ...
J Patrik, Hornak, David, Reynoso
openaire   +2 more sources

Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin

European Journal of Drug Metabolism and Pharmacokinetics, 2018
Delafloxacin has recently received approval by the US Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections. This article provides a balanced and comprehensive systematic critique of the literature in order to provide an up-to-date summary of its clinical pharmacology. Oral delafloxacin is rapidly absorbed
Jennifer, Shiu, Grace, Ting, Tony Kl, Kiang   +2 more
openaire   +2 more sources

Susceptibility of Yersinia enterocolitica to the novel fluoroquinolone delafloxacin

Diagnostic Microbiology and Infectious Disease, 2020
Minimum inhibitory concentration to delafloxacin and ciprofloxacin were performed with Y. enterocolitica, Y. frederiksenii and Y. kristensenii. All organisms were sensitive to delafloxacin and ciprofloxacin. Our study indicates that delafloxacin may have a reasonable in vitro susceptibility profile against Yersinia among the species studied, which has ...
Beverley C, Millar, John E, Moore
openaire   +2 more sources